Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
38.70
+1.27 (3.39%)
Aug 4, 2026, 4:00 PM EDT - Market closed
Rigel Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 60.82 | 40.58 | 56.75 | 32.79 | 24.46 | 18.89 |
Short-Term Investments | 34.51 | 114.38 | 20.58 | 24.15 | 33.75 | 106.08 |
Cash & Short-Term Investments | 95.33 | 154.96 | 77.32 | 56.93 | 58.21 | 124.97 |
Cash Growth | -12.04% | 100.41% | 35.81% | -2.19% | -53.42% | 117.99% |
Accounts Receivable | 56.04 | 51.76 | 41.62 | 30.55 | 40.32 | 15.47 |
Inventory | 14.37 | 11.51 | 6 | 5.52 | 9.12 | 6.62 |
Other Current Assets | 19.79 | 21.94 | 10.17 | 6.26 | 8.26 | 7.41 |
Total Current Assets | 185.53 | 240.17 | 135.1 | 99.27 | 115.9 | 154.47 |
Net Property, Plant & Equipment | 0.65 | 0.92 | 0.25 | 1.03 | 2.79 | 11.89 |
Other Intangible Assets | 93.88 | 24.75 | 27.1 | 13.88 | 14.95 | - |
Other Long-Term Assets | 241.01 | 247.76 | 1.53 | 3.06 | 0.64 | 0.97 |
Total Assets | 521.07 | 513.59 | 163.98 | 117.23 | 134.28 | 167.33 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.01 | 7.19 | 3.34 | 7.14 | 22.51 | 3.8 |
Accrued Expenses | 23.49 | 28.9 | 25.96 | 17.52 | 23.06 | 25.85 |
Current Portion of Long-Term Debt | 39.24 | 29.81 | 7.27 | 7.23 | - | - |
Current Portion of Leases | 0.66 | 0.61 | 0.29 | 0.69 | 1.13 | 9.89 |
Unearned Revenue | - | - | - | 1.36 | 1.37 | 2.6 |
Other Current Liabilities | 28.19 | 32.72 | 26.44 | 19.33 | 17.14 | 21.42 |
Total Current Liabilities | 95.59 | 99.24 | 63.3 | 53.27 | 65.21 | 63.55 |
Long-Term Debt | - | 22.48 | 52.41 | 52.37 | 39.45 | 19.91 |
Long-Term Leases | 0.06 | 0.4 | - | 0.29 | 0.97 | 0.76 |
Other Long-Term Liabilities | - | - | 44.98 | 39.94 | 42.26 | 52.73 |
Total Long-Term Liabilities | 0.06 | 22.88 | 97.39 | 92.6 | 82.68 | 73.4 |
Total Liabilities | 95.64 | 122.11 | 160.69 | 145.87 | 147.9 | 136.95 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.17 | 0.17 |
Additional Paid-in Capital | 1,423 | 1,414 | 1,393 | 1,379 | 1,369 | 1,354 |
Accumulated Other Comprehensive Income | -0.15 | 0.18 | 0.01 | 0.01 | -0.15 | -0.1 |
Retained Earnings | -997.1 | -1,023 | -1,390 | -1,408 | -1,382 | -1,324 |
Shareholders' Equity | 425.42 | 391.48 | 3.29 | -28.64 | -13.62 | 30.37 |
Total Liabilities & Equity | 521.07 | 513.59 | 163.98 | 117.23 | 134.28 | 167.33 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 39.95 | 53.3 | 59.97 | 60.58 | 41.55 | 30.57 |
Net Cash (Debt) | 55.38 | 101.65 | 17.36 | -3.65 | 16.65 | 94.4 |
Net Cash Growth | 16.99% | 485.69% | - | - | -82.36% | 417.56% |
Net Cash Per Share | 2.83 | 5.40 | 0.98 | -0.21 | 0.98 | 5.54 |
Book Value | 425.42 | 391.48 | 3.29 | -28.64 | -13.62 | 30.37 |
Book Value Per Share | 21.76 | 20.78 | 0.19 | -1.65 | -0.80 | 1.78 |
Tangible Book Value | 331.54 | 366.73 | -23.81 | -42.52 | -28.57 | 30.37 |
Tangible Book Value Per Share | 16.96 | 19.47 | -1.35 | -2.44 | -1.68 | 1.78 |